文献速递消化道肿瘤与早癌消化内镜

在多样化社区人群中验证基于实验室检测与人口学数据识别结直肠癌风险患者的算法

Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-29

在美国Kaiser Permanente Northern California成员中开展巢式病例对照研究,验证基于血常规和人口学数据的机器学习算法识别结直肠癌高风险患者的能力。高评分(特异度≥97%)识别未来6个月内结直肠癌诊断的灵敏度为35.4%(95%CI 33.8-36.7),AUROC为0.78(95%CI 0.77-0.78);高评分者早期结直肠癌OR为13.1(95%CI 11.8-14.3),晚期OR为24.8(95%CI 22.4-27.3)。算法识别出3%需进一步检查的人群,并识别出35%在未来6个月内确诊结直肠癌的患者。

要点

  • 高评分(特异度≥97%)识别未来6个月内结直肠癌的灵敏度为35.4%,AUROC为0.78。
  • 高评分者未来6个月内早期结直肠癌OR为13.1,晚期结直肠癌OR为24.8。
  • 高评分者近端癌OR为34.7,远端癌OR为12.1;算法准确性随血检与诊断间隔延长而下降。

核心结论

  • 验证了基于血常规和人口学数据的预测模型可识别结直肠癌高风险患者,算法识别出3%需进一步检查的人群和35%在未来6个月内确诊结直肠癌的患者。

研究设计与样本

  • 巢式病例对照研究,使用Kaiser Permanente Northern California成员1996-2015年数据。
  • 病例为50-75岁接受全血细胞计数、计数时无既往或当前结直肠癌诊断、随后确诊结直肠癌的队列成员。

主要发现

  • 高评分识别未来6个月内结直肠癌诊断的灵敏度为35.4%(95%CI 33.8-36.7),AUROC为0.78(95%CI 0.77-0.78)。
  • 高评分者未来6个月内早期结直肠癌OR为13.1(95%CI 11.8-14.3),晚期结直肠癌OR为24.8(95%CI 22.4-27.3)。
  • 高评分者近端癌OR为34.7(95%CI 31.5-37.7),远端癌OR为12.1(95%CI 10.1-13.9)。
  • 算法准确性随血检结果与结直肠癌诊断间隔时间延长而下降,性能不因性别或种族而异。

关键数值与推荐

  • 高评分定义为特异度≥97%。
  • 高评分识别未来6个月内结直肠癌的灵敏度为35.4%(95%CI 33.8-36.7),AUROC为0.78(95%CI 0.77-0.78)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Approximately 30%-40% of screening-eligible adults in the United States are not up to date with colorectal cancer (CRC) screening. We aimed to validate a predictive score, generated by a machine learning algorithm with common laboratory test data, to identify patients at high risk for CRC in a large, community-based, ethnically diverse cohort. METHODS: We performed a nested case-control study using data from members of Kaiser Permanente Northern California (1996-2015). Cases were cohort members who received a complete blood cell count at ages 50-75 y, did not have a prior or current diagnosis of CRC diagnosis at the time of the blood cell count, and were subsequently diagnosed with CRC. We used data from the cohort to validate the ability of an algorithm that uses laboratory and demographic information to identify patients at increased risk for CRC. Test performance was evaluated using area under the receiver operating characteristic curve (AUROC) and odds ratios (OR) with 95% CI values to compare high (defined as 97% specificity or more) vs low scores. RESULTS: A high score from the algorithm identified patients with a CRC diagnosis within the next 6 months with 35.4% sensitivity (95% CI, 33.8-36.7) and an AUROC of 0.78 (95% CI, 0.77-0.78). Patients with a high score had an increased risk of diagnosis with early-stage CRC (OR, 13.1; 95% CI, 11.8-14.3) and advanced stage CRC (OR, 24.8; 95% CI, 22.4-27.3) within the next 6 months. In patients with high scores, the ORs for proximal and distal cancers were 34.7 (95% CI, 31.5-37.7) and 12.1 (95% CI, 10.1-13.9), respectively. The algorithm's accuracy decreased with the time interval between blood test result and CRC diagnosis; performance did not differ by sex or race. CONCLUSIONS: We validated a predictive model that uses complete blood cell count and demographic data to identify patients at high risk of CRC. The algorithm identified 3% of the population who require an investigation and identified 35% of patients who received a diagnosis of CRC within the next 6 months.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Schneider JL, Layefsky E, Udaltsova N, et al. Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. Clin Gastroenterol Hepatol. 2020. PMID: 32360824. doi:10.1016/j.cgh.2020.04.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。